Priced like the old business, running like a new one: management is redirecting the call away from the metric investors
The model's full reasoning — Q2 2023 call → NOThe question asks whether management repeatedly redirects attention away from the conventional yardstick toward a different part of the business that is already earning today, and indicates the record hasn't caught up. Let me analyze the transcript: 1. The company is Akoya Biosciences, a spatial biology company. The conventional yardstick appears to be instrument placements/revenue, and the overall revenue growth. 2. Management discusses: - Record revenue of $23.5M, 31% growth - Record system placements of 72 instruments - Cumulative installed base of 1,064 instruments - Focus on reagent revenue growth and pull-through - New product launches (PhenoCode reagent panels, Fusion 2.0 upgrades) - Services revenue growing 73% 3. Does management set aside the conventional yardstick? The call is largely organized around the usual metrics - revenue, instrument placements, installed base, reagent revenue. Management discusses all of these as core to the business. 4. Is there a different part of the business put forward as already earning? Management discusses: - Reagent revenue growth (29% growth) - Services revenue (73% growth) - The translational/clinical market opportunity - The CRO network - The CLIA Lab and Acrivon partnership 5. Does management indicate the record hasn't caught up? Management discusses that reagent pull-through is increasing, that the PhenoCycler-Fusion is driving higher pull-through, and that new panels will drive future growth. But this seems like normal forward-looking commentary about growth drivers, not a reframing of the yardstick. The call is a conventional earnings call organized around the company's usual metrics - revenue, instrument placements, installed base, reagent revenue, gross margin, operating expenses. Management discusses growth drivers and new products but doesn't set aside the conventional yardstick or say the market is measuring the wrong thing. Management does emphasize reagent revenue growth and pull-through as a focus, but this is presented as a growth initiative, not as a reframing of how the company should be judged. The company still reports and discusses instrument placements prominently.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| NOAH | Noah Holdings Limited | Q1 2024 | 2024-05-30 | D |
| DUOT | Duos Technologies Group, Inc. | Q4 2023 | 2024-04-01 | F |
| OPAD | Offerpad Solutions Inc. | Q3 2023 | 2023-11-01 | C |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| CALX | Calix, Inc. | Q1 2023 | 2023-04-20 | C+ |
| WD | Walker & Dunlop, Inc. | Q2 2022 | 2022-08-09 | C+ |
| LC | LendingClub Corporation | Q4 2021 | 2022-01-26 | A |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| LPTH | LightPath Technologies, Inc. | Q4 2021 | 2021-09-09 | D |
| LOB | Live Oak Bancshares, Inc. | Q3 2018 | 2018-10-25 | C+ |
SPT · Q2 2023 → YESThe question is whether management repeatedly redirects attention away from the conventional measure toward a different part of the business that's already earning today, and indicates that this diffe...YES The transcript shows management repeatedly reframing away from the conventional total ARR/revenue growth metric (which is being distorted by unpredictable low-end non-core ARR) toward the higher-quality up-market/enterprise segment that is already delivering record new business ACVs, 50%+ YoY growth, and 43% of 2023 ARR. They explicitly set the low-end aside by removing it from forecasts and modeling to give “greatest visibility,” note that Q2 ARR growth will be the lowest pace of the year because of this change, and indicate the reported figures still reflect the old mix while the new up-market story is already earning today (with Tagger adding further upside not yet reflected). This creates the coherent posture of redirecting attention from the headline growth number outsiders watch to the part of the business that is already producing real results.
WD · Q2 2022 → YESThe question is about whether management repeatedly redirects attention away from the conventional measure to a different part of the business that's already earning today, and indicates that this isn...YES The transcript shows management repeatedly reframing the discussion away from the conventional multifamily agency lender yardstick (origination volumes, GSE lending, MSR-driven EPS) toward the diversified services and asset-management businesses that are already generating substantial cash revenue and EBITDA today. They explicitly set the old metric aside by introducing adjusted EPS to “strip out non-cash mortgage servicing rights,” highlight the shift from “lending-centric” to “broader technology-enabled financial services,” and note that segment results now provide “more transparency into our operating structure.” They point to debt brokerage, property sales, SAM (Alliant, Zelman), small-balance lending, and appraisals as the new earning engines, describing their concrete contributions (e.g.
CALX · Q1 2023 → YESThe question is about whether management repeatedly redirects attention away from the conventional measure to a different part of the business that's already earning today, and indicates that this isn...YES The transcript shows management repeatedly framing the company as operating in a "new market" centered on platforms, clouds, and managed services—distinct from the legacy hardware/cyclical model—while highlighting real earnings from these areas (e.g., 988 BSPs deploying platforms, 865 cloud customers, 334 with 41 new managed services in Q1, record Intelligent Access EDGE revenue). They indicate this is already producing revenue and customer adoption but remains early-stage ("this is the beginning," "early stage of where we are in this new market"), with reported results still reflecting the prior hardware-focused picture.